Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.40 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.40 |
| ▸ | PLK4 | O00444 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.40 |
| ▸ | FLT4 | P35916 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | BLK | P51451 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588605 | 0.91 | KDR (0.38) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL2584315 | 0.90 | HDAC4 (0.37) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL2593137 | 0.89 | KDR (0.36) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL14737004 | 0.88 | KDR (0.36) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL14737628 | 0.88 | KDR (0.38) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL14737232 | 0.87 | KDR (0.37) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL2582205 | 0.87 | CNR1 (0.39) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL2584400 | 0.87 | KDR (0.37) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL2591355 | 0.86 | KDR (0.35) | KDRROCK1ROCK2RPS6KB1TAOK1 | |
| SCHEMBL2592846 | 0.86 | PIK3CD (0.35) | KDRROCK1ROCK2RPS6KB1TAOK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| EP-2563770-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134468-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | KDR 1971/4885ROCK1 48/4885ROCK2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.